This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jokhdar, H.
Right arrow Articles by Baxter, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jokhdar, H.
Right arrow Articles by Baxter, D.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2004, p. 83-88, Vol. 11, No. 1
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.1.83-88.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Immunologic Hyporesponsiveness to Serogroup C but Not Serogroup A following Repeated Meningococcal A/C Polysaccharide Vaccination in Saudi Arabia

Hani Jokhdar,1* Ray Borrow,2,{dagger} Abdulrazaq Sultan,3 Mousaed Adi,4 Christine Riley,2,{dagger} Emily Fuller,2,{dagger} and David Baxter1

School of Epidemiology and Health Science, Medical School, The University of Manchester, Manchester M13 9PT,1 Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Manchester M20 2LR, United Kingdom,2 School of Medicine and Allied Sciences, University of Umm Al-Qura, Makkah ,3 Medical Services, King Abdul Aziz International Airport Project, Jeddah 21441, Kingdom of Saudi Arabia4

Received 20 June 2003/ Returned for modification 24 September 2003/ Accepted 20 October 2003

In Saudi Arabia, vaccination with the meningococcal A/C polysaccharide (MACP) vaccine is advised every 3 years. A clinical outcome study was performed to test the effect of repeat vaccination with the MACP vaccine on the immune responses among Saudi nationals who live in the Makkah and Jeddah areas. Subjects (n = 230) aged 10 to 29 years were selected: 113 subjects with two or more prior vaccinations with the MACP vaccine, 79 subjects with one prior vaccination with the MACP vaccine, and 38 subjects naïve to vaccination with the MACP vaccine. All subjects received the MACP vaccine in 2002, and serum bactericidal antibody (SBA) titers were measured before and 1 month after vaccination with the MACP vaccine. For serogroup C, geometric mean SBA titers 1 month following vaccination with the MACP vaccine were 708.6 (95% confidence interval [CI], 217.5 to 2,308.9) for those naïve to prior vaccination with the MACP vaccine, and they were significantly higher (P < 0.0001) than 25.0 (95% CI, 12.4 to 50.2) for those who had received one prior vaccination with the MACP vaccine and 32.4 (95% CI, 18.7 to 56.4) for those who had received two or more doses of the MACP vaccine. For serogroup A, the geometric mean SBA titer 1 month after receipt of the MACP vaccine was 1,649.3 (95% CI, 835.2 to 3,256.9) for those naïve to prior vaccination, and the titers were lower (P = 0.67) than 2,185.7 (95% CI, 1,489.4 to 3,207.7) for those who had received one prior dose of the MACP vaccine and significantly lower (P = 0.042) than 3,540.8 (95% CI, 2,705.2 to 4,634.5) for those who had received two or more doses of the MACP vaccine. For serogroup C, the proportions of nonresponders (SBA titers, <8) were 19% for the naïve cohort, 52% for the cohort with one prior vaccination, and 49% for the cohort with two or more prior vaccinations. Following repeated doses of the MACP vaccine, hyporesponsiveness to serogroup C is evident, with high percentages of MACP vaccinees having SBA titers below the putative protective SBA titer. Serogroup A responses following vaccination with the MACP vaccine were boosted. Introduction of the serogroup C conjugate vaccine would provide long-term protection against serogroup C disease; however, quadrivalent conjugate vaccines are required to provide long-time protection against disease caused by serogroups A, W135, and Y.

* Corresponding author. Mailing address: School of Epidemiology and Health Science, Medical School, The University of Manchester, Oxford Rd., Manchester M13 9PT, United Kingdom. Phone: 44-161-882 0036. Fax: 44-161-275 5595. E-mail: hani.j{at}btinternet.com.

{dagger} Present address: Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom.

Clinical and Diagnostic Laboratory Immunology, January 2004, p. 83-88, Vol. 11, No. 1
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.1.83-88.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Balmer, P., Cant, A. J, Borrow, R. (2007). Anti-pneumococcal antibody titre measurement: what useful information does it yield?. J. Clin. Pathol. 60: 345-350 [Abstract] [Full Text]  
  • Al-Mazrou, Y., Khalil, M., Borrow, R., Balmer, P., Bramwell, J., Lal, G., Andrews, N., Al-Jeffri, M. (2005). Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age. Infect. Immun. 73: 2932-2939 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»